deltatrials
Enrolling By Invitation PHASE1 INTERVENTIONAL 2-arm NCT07262268

A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia

A Phase 1b, Double-Blind, Crossover Study of BHV-7000 in Patients With Inherited Erythromelalgia (IEM) With NaV1.7 Gain of Function Mutations

Sponsor: Biohaven Therapeutics Ltd.

Conditions Familial Erythromelalgia
Interventions BHV-7000 Placebo
Updated 2 times since 2026 Last updated: Jan 16, 2026 Started: Jan 15, 2026 Primary completion: Jun 30, 2026 Completion: Jul 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Familial Erythromelalgia and is currently ongoing. Biohaven Therapeutics Ltd. leads this study, which shows 2 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshotNot Yet Recruiting~Feb 2026 – present · 6 months · monthly snapshotEnrolling By Invitation

Change History

2 versions recorded

  1. Feb 2026 — Present [monthly]

    Enrolling By Invitation PHASE1

    Status: Not Yet Recruiting → Enrolling By Invitation

  2. Jan 2026 — Feb 2026 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Biohaven Therapeutics Ltd.
Data source: Biohaven Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations